Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.
Laboratories that purchase PGDx Elio genomic profiling tests will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation.
The partners will use PacBio's HiFi sequencing to develop assays for carrier screening, evaluating immune system responses, and diagnosing heritable diseases.
The firms will provide access to tumor profiling tests for both tissue and plasma samples, specifically PGDx's elio tissue complete and elio plasma resolve assays.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
